Cord Blood-derived NK Cells

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
94 patients (estimated)
Sponsors
MD Anderson Cancer Center
Tags
Adoptive Cellular Therapy, Chemotherapy, Natural Killer (NK) Cells (Allogeneic)
Trial Type
Treatment
Last Update
3 weeks ago
SparkCures ID
1562
NCT Identifier
NCT05092451

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.